Avi Mazaltov - VBI Vaccines Global SciVac
Insider
Avi Mazaltov is Global SciVac of VBI Vaccines
| Age | 62 |
| Phone | 617 830 3031 |
| Web | https://www.vbivaccines.com |
Avi Mazaltov Latest Insider Activity
Tracking and analyzing the buying and selling activities of Avi Mazaltov against VBI Vaccines stock is an integral part of due diligence when investing in VBI Vaccines. Avi Mazaltov insider activity provides valuable insight into whether VBI Vaccines is net buyers or sellers over its current business cycle. Note, VBI Vaccines insiders must abide by specific rules, including filing SEC forms every time they buy or sell VBI Vaccines'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Avi Mazaltov over a year ago Acquisition by Avi Mazaltov of 52500 shares of VBI Vaccines subject to Rule 16b-3 |
VBI Vaccines Management Efficiency
The company has return on total asset (ROA) of (0.2915) % which means that it has lost $0.2915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1959) %, meaning that it created substantial loss on money invested by shareholders. VBI Vaccines' management efficiency ratios could be used to measure how well VBI Vaccines manages its routine affairs as well as how well it operates its assets and liabilities.VBI Vaccines currently holds 53.04 M in liabilities with Debt to Equity (D/E) ratio of 0.32, which is about average as compared to similar companies. VBI Vaccines has a current ratio of 2.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about VBI Vaccines' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Schlumpberger | Anixa Biosciences | N/A | |
| Robert Lutz | Ibio Inc | 55 | |
| Uma Sinha | BridgeBio Pharma | 66 | |
| Eli Wallace | BridgeBio Pharma | 57 | |
| CPA JD | Jaguar Animal Health | 60 | |
| Timothy Rolph | Akero Therapeutics | 70 | |
| Dan Pavicich | Ardelyx | N/A | |
| Michael Shine | Ocugen Inc | N/A | |
| Mark Newman | GeoVax Labs | 69 | |
| Stephen Cheng | Allogene Therapeutics | N/A | |
| Rafael MD | Allogene Therapeutics | 60 | |
| Thomas Trimarchi | BridgeBio Pharma | N/A | |
| Robert Blanks | Ardelyx | 64 | |
| Zara Gaudioso | Ocugen Inc | N/A | |
| Tiffany MBA | Ocugen Inc | N/A | |
| Daniel MD | Tonix Pharmaceuticals Holding | N/A | |
| Dr Stapleton | Vaxart Inc | 53 | |
| Dr DVM | Ibio Inc | 54 | |
| William JD | Akero Therapeutics | 51 | |
| Claudine Bruck | Annovis Bio | 65 | |
| Carol Lizak | Jaguar Animal Health | 60 | |
Management Performance
| Return On Equity | -4.2 | |||
| Return On Asset | -0.29 |
VBI Vaccines Leadership Team
Elected by the shareholders, the VBI Vaccines' board of directors comprises two types of representatives: VBI Vaccines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VBI. The board's role is to monitor VBI Vaccines' management team and ensure that shareholders' interests are well served. VBI Vaccines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VBI Vaccines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam Buckley, Vice President - Operations and Project Management | ||
| FRCPC MD, Chief Officer | ||
| FCMA FCMA, CEO Pres | ||
| Christopher McNulty, CFO and Head of Business Development | ||
| Nicole Anderson, Director Relations | ||
| Avi Mazaltov, Global SciVac | ||
| Misha Nossov, Senior Europe | ||
| David Anderson, Chief Scientific Officer | ||
| Jeffery FCMA, CEO President | ||
| Nell Beattie, Chief Officer | ||
| Athena Kartsaklis, Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller | ||
| John Dillman, Chief Officer |
VBI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VBI Vaccines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.2 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (9.68) % | |||
| Current Valuation | 38.92 M | |||
| Shares Outstanding | 28.68 M | |||
| Shares Owned By Insiders | 6.76 % | |||
| Shares Owned By Institutions | 13.00 % | |||
| Number Of Shares Shorted | 276.87 K | |||
| Price To Earning | (3.79) X | |||
| Price To Book | 1.24 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in VBI Stock
If you are still planning to invest in VBI Vaccines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VBI Vaccines' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stocks Directory Find actively traded stocks across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |